Media about us

16 March 2016

Multiple STIs could be detected with researchers developing a single 30 minute test

HealthCanal

One test that could detect four of the most common sexually transmitted infections in 30 minutes and allow them to be rapidly treated, will be developed by St George’s, University of London and diagnostics company Atlas Genetics.

15 March 2016

Despite Turbulence, Russia’s Pharma Market Holds Promise

Kim Ribbink / PharmaVoice.com

The world’s largest nation, Russia remains an attractive market for most industries. Nevertheless, the country has struggled through a rough economic period, rocked by a drop in the value of the currency and turbulence in the oil market. Geopolitical pressures have raised challenges, including sanctions imposed on the country.

04 March 2016

Syndax braves a market tempest in second IPO try, scores a $53M raise

John Carroll / FierceBiotech

Syndax ($SNDX) has joined a small group of biotechs that has managed to price an IPO in the face of gale force market headwinds. The biotech had to go well under its projected range, though, and settle for $12.

03 March 2016

Syndax Cuts Price But Bags $53M in Second IPO Try

Ben Fidler / Xconomy

Over the past year, Syndax Pharmaceuticals has altered its strategic course and hired new management to implement it. And it looks like that change was big enough to propel Waltham, MA-based Syndax through the IPO queue on its second attempt since late 2014—albeit not on the terms the company had hoped for.

24 February 2016

Syndax readies its 2nd IPO attempt during a market tempest

John Carroll / FierceBiotech

Looking to cash in on its eventful past year, Syndax is upping its bet on a turbulent market with an IPO that will seek to garner about $66 million. The last time Syndax made a try at an IPO, it set out for a $60 million windfall. But this time, it's looking to trade on the rep of its new, high-profile CEO--AstraZeneca vet Briggs Morrison--and a string of partnerships with a who's who in immuno-oncology by selling 4.4 million shares at $14 to $16 per share. At most, it could gain up to $70 million, though the odds against a top-of-the-range response are intimidating.

19 February 2016

Groundbreaking STI test can detect chlamydia in 30 minutes

The Telegrah / Lifestyle

The Atlas io system was created by the University of Bath's spin-off biotech company Atlas Genetics in 2005. It has now won approval from the EU to be sold. The development means that patients can be tested and treated for the disease within a single clinic visit.

08 February 2016

University of Bath biotech spin-out wins EU approval for ground-breaking chlamydia test

Julia Bradshaw / The Telegraph

A small biotech that started life at the University of Bath has won approval from European regulators to sell a device that tests for the sexually transmitted disease chlamydia in just 30 minutes.

04 February 2016

Blood Test Offers An Amazing View Of Metastatic Prostate Cancer Cells

Elaine Schattner / Forbes

A few months ago, I met with Murali Prahalad, CEO of Epic Sciences (San Diego). We discussed the company’s methods of processing blood samples to store, identify and examine circulating tumor cells (CTCs). Since then I’ve been following reports on Epic’s method and other, competing CTC platforms.

01 February 2016

Biomarker Discovery Gets a Fix on Cancer

Cancer Kathy Liszewski / Genetic Engineering & Biotechnology News

ust as signposts provide information, direction, and guidance, so too cancer biomarkers can better reveal the complex, dynamic, and heterogeneous landscape of malignancies. Such information is critical for creating better cancer diagnostics, prognostics, and therapeutics, but the journey to find just the right biomarker is often a long and winding road.

28 January 2016

Subscribe to Cancer Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

GenomeWeb

Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.